Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identifying the molecular mode of action of itraconazole in colorectal cancer

ABSTRACT: Identifying the molecular mode of action of itraconazole in colorectal cancer

PROVIDER: PRJNA454881 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7108390.fastq.gz	Fastqsanger.gz
	SRR7108400.fastq.gz	Fastqsanger.gz
	SRR7108391.fastq.gz	Fastqsanger.gz
	SRR7108401.fastq.gz	Fastqsanger.gz
	SRR7108392.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

Identifying the molecular mode of action of itraconazole in colorectal cancer

Project description:Two cell lines (HT55 and SW948) were found responsive to itraconazole treatment. To identify the mode of action cells were treated with itraconazole or control (DMSO) and then subjected to RNAseq analysis once the phenotype had developed

2018-05-21 | GSE114013 | GEO

Praziquantel mode of action and resistance

Project description:Praziquantel mode of action and resistance

| PRJEB1281 | ENA

Itraconazole targets cell cycle heterogeneity in colorectal cancer

Project description:Itraconazole targets cell cycle heterogeneity in colorectal cancer

| PRJNA454876 | ENA

Praziquantel mode of action and resistance

Project description:This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/The drug Praziquantel is the most commonly used drug for parasitic flatworms. It is currently being increasingly used in mass drug administration programmes, raising concerns over whether resistance will develop. Although widely used, its mode of action was until very recently uncertain. This study will investigate the praziquantel mode of action and resistance by sequencing the transcriptomes of Dugesia japonica and different stages and strains of S. mansoni.

2013-05-13 | E-ERAD-135 | biostudies-arrayexpress

Linking toxicant physiological mode of action with induced gene expression changes in Caenorhabditis elegans

Project description:This SuperSeries is composed of the following subset Series: GSE21008: Linking toxicant physiological mode of action with induced gene expression changes in Caenorhabditis elegans: atrazine GSE21010: Linking toxicant physiological mode of action with induced gene expression changes in Caenorhabditis elegans: cadmium GSE21011: Linking toxicant physiological mode of action with induced gene expression changes in Caenorhabditis elegans: fluoranthene Refer to individual Series

2010-03-23 | E-GEOD-21012 | biostudies-arrayexpress

Cutaneous squamous cell carcinoma A431 cells treated with itraconazole

Project description:The role of itraconazole in cSCC was still unclear. Our objective is to explore the therapeutic potential of itraconazole in cSCC and investigate its molecular mechanism. We proved itraconazole inhibits the growth of cSCC by several pathways.

2022-01-25 | GSE191037 | GEO

Mode of action studies with DNDi6174 in Leishmania donovani

Project description:Mode of action studies with DNDi6174 in Leishmania donovani

| PRJEB45584 | ENA

Antibacterial mode of action of alpha-mangostin on Staphylococcus epidermidis

Project description:Antibacterial mode of action of alpha-mangostin on Staphylococcus epidermidis

| PRJNA450895 | ENA

Novel insights into the mode of action of 1,4 dioxane

Project description:Novel insights into the mode of action of 1,4 dioxane

| PRJNA663909 | ENA

Antibacterial mode of action of alpha-mangostin on Staphylococcus epidermidis

Project description:Alpha-mangostin (α-MG) is a natural xanthone reported to exhibit rapid bactericidal activity against Gram-positive bacteria, and may therefore have potential clinical application in healthcare sectors. This study sought to identify the antibacterial mode of action of α-MG against Staphylococcus epidermidis RP62A through RNA-sequencing technology.

2018-04-19 | GSE113302 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data